期刊文献+

胃癌免疫检查点抑制剂作用机制及最新研究进展 被引量:5

Mechanism and recent progress of gastric cancer in immunological checkpoint inhibitors
下载PDF
导出
摘要 胃癌治疗方法有限,预后较差。目前肿瘤免疫治疗因其显著的生存获益已成为除手术、化疗、放疗及靶向治疗之外有效的新型肿瘤治疗手段。免疫检查点抑制剂作为肿瘤免疫治疗的方法之一,已被批准用于多种肿瘤的治疗,提示胃癌免疫治疗时代已经到来。本文介绍了免疫治疗中免疫检查点抑制剂的作用机制及相关研究进展。 The treatment of gastric cancer is limited and the prognosis is poor.Tumor immunotherapy has been an effective new treatment for cancer in addition to surgery,chemotherapy,radiotherapy and targeted therapy because of its remarkable survival benefit.As one of the methods of tumor immunotherapy,immunological checkpoint inhibitors have been approved for the treatment of various tumors,suggesting that the era of gastric cancer immunotherapy has arrived.This article describes the mechanism of action and related research progress of immunological checkpoint inhibitors in immunotherapy.
作者 姚洋 张艳桥 YAO Yang;ZHANG Yanqiao(Harbin Medical University Cancer Hospital,Harbin 150081,China)
出处 《实用肿瘤学杂志》 CAS 2019年第4期371-375,共5页 Practical Oncology Journal
关键词 胃癌 免疫治疗 免疫检查点抑制剂 Gastric cancer Immunotherapy Immunological checkpoint inhibitors
  • 相关文献

参考文献4

二级参考文献45

  • 1Hodi FS, O' Day S J, McDermott DF, et al. Improved sur- vival with ipilimumab in patients with metastatic melano- ma[J]. N Engl J Meal,2010,363(8) :711 -723.
  • 2Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 sys- tem of T cell costimulation [ J ]. Annu Rev Immnnol, 1996,14:233 - 258.
  • 3Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocyto- sis of CD80 and CD86:a molecular basis for the cell-ex- trinsic function of CTLA-4 [ J ]. Science, 2011, 332 (6029) :600 - 603.
  • 4Rudd CE,Taylor A, Schneider H. CD28 and CTLA-4 co- receptor expression and signal transduction [ J ]. Immunol Rev ,2009 ,229 ( 1 ) : 12 - 26.
  • 5O'Mahony D,Janik JE. Comment on "Analysis of the cel- lular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade" [ J ]. J Immu- nol,2006,176(9) :5136.
  • 6Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade [ J ]. J Immunol, 2005,175( 11 ) :7746 -7754.
  • 7Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mecha- nisms [ J ]. Mol Cell Biol,2005,25 (21) :9543 - 9553.
  • 8Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3 + regulatory T cell function [ J ]. Science, 2008,322 (5899) :271 - 275.
  • 9Spranger S, Koblish HK, Horton B, et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and pro- liferation of CD8 ( + ) T cells directly within the tumor microenvironment[ J]. J Immunother Cancer,2014,2:3.
  • 10Grosso JF, Goldberg MV, Getnet D, et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chron- ically stimulated CD8 T cells[ J]. J Immunol,2009,182 ( 11 ) :6659 -6669.

共引文献29

同被引文献31

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部